StimCardio’s NeuroPulse Study Shows Promise in Reducing Atrial Fibrillation Events with Wearable Technology

Introduction

Recently, StimCardio Medical announced remarkable findings from their NeuroPulse study, showcasing how a non-invasive wearable device can significantly improve outcomes for patients dealing with recurrent atrial fibrillation (AF) after ablation treatments. The results were presented at the prestigious HRX Live 2026 and also published in the peer-reviewed journal, Heart Rhythm.

Study Background

The NeuroPulse study was designed as a randomized, double-blind, sham-controlled trial, a rigorous methodology that adds credibility to its findings. The primary goal was to assess the effectiveness of non-invasive median nerve stimulation (MNS) administered through a wearable device in patients who had undergone AF ablation. This new approach aims to engage peripheral neural pathways, influencing the autonomic regulation of cardiac rhythm, offering an alternative to traditional methods of further ablating cardiac tissue.

Key Findings

Among the notable outcomes of the study, patients receiving MNS achieved a 90% freedom from atrial arrhythmias at the six-month mark. In stark contrast, only 80.8% were free from arrhythmias in the sham treatment group. Although these results weren't statistically significantly different, the 12 recorded events from the MNS group compared to 28 in the sham group showcased a substantial reduction in recurrent atrial arrhythmias, highlighting a p-value of 0.025, reflecting strong evidence of MNS efficacy.

Furthermore, the research reported no serious adverse events related to the MNS device, promoting its safety profile.

The Need for Improved Treatments

While advancements like pulsed field ablation (PFA) have revolutionized AF treatment in recent years, a persistent efficacy gap remains—a fact underscored by previous studies. The 2023 ADVENT trial led by Dr. Vivek Y. Reddy illustrated that, despite technological advancements, the treatment success rates only modestly varied between new PFA methods (73.3%) and older thermal ablation techniques (71.3%).

Advantages of Non-Invasive Approaches

The significance of the NeuroPulse findings is emphasized by Dr. Reddy himself: “The question is not whether ablation works. It clearly does. The real query is how we improve outcomes for patients experiencing recurrent arrhythmia despite advanced technologies.” The study suggests that integrating non-invasive methods like MNS could be the key to solving this ongoing challenge, extending AF treatment into everyday life settings for patients.

Future Directions

StimCardio is poised to further explore these promising results through an upcoming pivotal trial. As explained by Amos Ziv, MSc, the founder and chief scientific officer of StimCardio, this technology represents a new frontier in AF management: “Our vision is to extend what electrophysiologists can do for patients beyond the ablation procedure.”

The development of Rhyvive™, a wrist-worn, physician-prescribed device designed to provide personalized neuromodulation and continuous physiological monitoring, reflects this vision in action. This device not only aims to address the limitations posed by traditional ablation procedures but also empowers patients to engage actively in their health management under professional supervision.

Conclusion

In summary, the NeuroPulse pilot study represents a significant leap forward in the approach to treating atrial fibrillation, emphasizing the potential of wearable technology in enhancing patient care. By securing additional funding for more extensive trials, StimCardio anticipates establishing a new category of personalized cardiac rhythm treatment that could drastically alter the landscape of AF management. With its promise in achieving better outcomes for patients, the future of atrial fibrillation treatment may well lie in innovative, non-invasive interventions that allow for more proactive personal involvement in healthcare.

For further information, investigations, and reviews of the study, please visit StimCardio's website.